IonQ reaches 1,000 patents milestone with new quantum computing grants
Cosmos Health Inc. (NASDAQ:COSM), a healthcare company with a market capitalization of $12.8 million and currently trading at a price-to-book ratio of 0.48, has reported that its Chief Executive Officer, Grigorios Siokas, acquired 174,172 shares of the company on May 21, 2025. According to InvestingPro analysis, the company appears undervalued based on its Fair Value estimate. The shares were obtained at a price of $0.4708 each, amounting to a total transaction value of $82,000. This acquisition was part of a debt exchange agreement, where Mr. Siokas received shares in lieu of a debt the company owed him. Following this transaction, Mr. Siokas now directly owns a total of 5,983,055 shares in Cosmos Health. The company operates with a significant debt burden and maintains a current ratio of 1.05, while generating gross profit margins of 9.39%. InvestingPro subscribers can access 8 additional key insights about COSM’s financial health and valuation metrics.
In other recent news, Cosmos Health Inc. has been granted an additional 180-day period by the Nasdaq Stock Market to meet the minimum bid price requirement, extending the deadline to November 3, 2025. This extension allows Cosmos Health more time to regain compliance with the Nasdaq listing standards, except for the bid price rule. Additionally, CEO Greg Siokas has increased his stake in the company, purchasing 1,466,764 common shares for a total of $526,000, reflecting his commitment to the company. In a strategic move, Cosmos Health has secured a contract manufacturing agreement through its subsidiary Cana Laboratories with Pharmex S.A. to produce 300,000 bottles per year of the antiseptic drug AMBITASOL 1L over a five-year period.
Moreover, Cosmos Health has expanded its presence into the Albanian market by launching its Sky Premium Life food supplements brand in partnership with Pharma Cell. The initial annual order from Pharma Cell is valued at $300,000, with plans for future expansion. These developments demonstrate Cosmos Health’s efforts to enhance revenue generation and expand its global footprint. The company continues to focus on strategic partnerships and manufacturing capabilities to support its growth aspirations. These recent activities are part of Cosmos Health’s broader strategy to strengthen cash flows and improve profitability.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.